LaserStock29 wrote: Thor6570 wrote:
6 for 6 so far ! There is more than enough information available to take a healthy position IMHO.
EXAS 126m shares 6.3b market cap pps $50+ for Cologuard.. A box gets shipped to your door and you poop in it, then get it checked for colon cancer..
Previous to Cologuard pps was at $3 bucks.
I like TLD-1433........ I think TLD-1633 will be the choice for GBM ... doctors seem to like the safety profile even more.. i pray they did the storage 6,12,18 month checks in parallel to our trial as to not waste time.
That would put TLT at 2 drugs instead of 1. $$$
For the Lung Cancer indication.. 'first line' absolutely no reason IMO that we can't take Concordias treatment plan and copy it and drop in /swap out Photofrin for TLD-1433 and get to it asap.. it's laser activated after all.
To me.. Patient 9 starts it... then if Roger drops the addition of two indications + TLD 1633...
should be a mega voltage upgrade.
Dude Rats were worth .78 then Phase 1b .49 ... delays in 2017 nerfed it so we're at .23
Theres hope for a pp to nuke it...... lol
*rolls eyes* wake me up when P9 is treated